Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Curatis increases revenue in first half by 51% and reduces loss
Curatis raised net revenue in H1 2026 by 51% to CHF 7.9 million, with product sales of CHF 7.4 million and service sales of CHF 0.6 million. The deficit shrank to CHF 0.4 million after −CHF 1.2 million the previous year, and cash and cash equivalents rose to CHF 3.6 million thanks to a convertible instrument placed in May for CHF 3 million. For 2026 the biotech company confirms the revenue guidance raised in June of around CHF 15 million and aims for a breakeven result. For its key project Corticorelin (C-PTBE-01), a meeting with the FDA to define the Phase‑III study design is planned for Q1 2027. » More on finanzen.net
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 8.6M | - |
| Gross profit | 268.67K | - |
| Net profit | -440.92K | - |
| EBITDA | -226.42K | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €105.3M |
Number of shares | 5.31M |
52-week high/low | €30.13 - €11.93 |
| Dividends | No |
Beta | -0.81 |
P/E ratio | -144.37 |
PEG ratio | 4.86 |
P/B ratio | 1.95 |
P/S ratio | 7.22 |
Company profile
| Name | Curatis Holding AG |
| CEO | Roland Rutschmann |
| Employees | 9 |
